documents incorporated reference parts portions registrants proxy statement annual meeting shareholders filed within days close iii registrants fiscal year proxy statement incorporated reference report reportitem part business general segments business geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis results operations financial condition quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules summary signatures exhibit index cautionary note regarding forwardlooking statements annual report johnson johnson 's publicly available documents contain forwardlooking statements within meaning safe harbor provisions us private securities litigation reform act management representatives johnson johnson subsidiaries company also may time time make forwardlooking statements forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations expected operating results financial performance impact planned acquisitions dispositions companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events subject uncertainties risks changes difficult predict many outside company 's control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize companys actual results financial condition could vary materially expectations projections expressed implied forwardlooking statements investors therefore cautioned rely forwardlooking statements risks uncertainties include limited risks related product development market success competition challenges uncertainties inherent innovation development new improved products technologies companys continued growth success depend including uncertainty clinical outcomes obtaining regulatory approvals health plan coverage customer access initial continued commercial success challenges companys ability obtain protect adequate patent intellectual property rights new existing products technologies us important markets impact patent expirations typically followed introduction competing biosimilars generics resulting revenue market share losses increasingly aggressive frequent challenges companys patents competitors others seeking launch competing generic biosimilar products potentially resulting loss market exclusivity rapid decline sales relevant product competition research development new improved products processes technologies result product process obsolescence competition reach agreement third parties collaboration licensing development marketing agreements products technologies competition basis costeffectiveness product performance technological advances patents attained competitors allegations companys products infringe patents intellectual property rights third parties could adversely affect companys ability sell products question require payment money damages future royalties risks related product liability litigation regulatory activity product efficacy safety concerns whether based scientific evidence potentially resulting product withdrawals recalls regulatory action part us food drug administration international counterparts declining sales reputational damage impact significant litigation government action adverse company including product liability claims increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations mcneilppc inc consent decree corporate integrity agreements johnson johnson pharmaceutical affiliates compliance agreements governments government agencies could result significant sanctions potential changes applicable laws regulations affecting us international operations including relating approval new products licensing patent rights sales promotion health care products access reimbursement pricing health care products services environmental protection sourcing raw materials changes tax laws regulations increasing audit scrutiny tax authorities around world exposures additional tax liabilities potentially excess reserves issuance new revised accounting standards financial accounting standards board securities exchange commission risks related companys strategic initiatives health care market trends pricing pressures resulting trends toward health care cost containment including continued consolidation among health care providers trends toward managed care shift toward governments increasingly becoming primary payers health care expenses restricted spending patterns individual institutional governmental purchasers health care products services due economic hardship budgetary constraints challenges companys ability realize strategy growth including externally sourced innovations development collaborations strategic acquisitions licensing marketing agreements potential heightened costs external arrangements due competitive pressures potential expected strategic benefits opportunities planned completed acquisition divestiture company including planned acquisition actelion ltd may realized may take longer realize expected potential expected benefits opportunities related planned restructuring actions medical device segment may realized may take longer realize expected including due required consultation procedures relating restructuring workforce market conditions possibility companys share repurchase program may delayed suspended discontinued risks related economic conditions financial markets operating internationally impact inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins potential changes exportimport trade laws regulations policies us uk countries including increased trade restrictions potential drug reimportation legislation impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations impact armed conflicts terrorist attacks us parts world including social economic disruptions instability financial markets risks related supply chain operations difficulties delays manufacturing internally within supply chain may lead voluntary involuntary business interruptions shutdowns product shortages withdrawals suspensions products market potential regulatory action interruptions breaches company 's information technology systems company 's vendors could result reputational competitive operational business harm well financial costs regulatory action reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect supply sourcing pricing materials used companys products investors also carefully read risk factors described item annual report description certain risks could among things cause companys actual results differ materially thoseexpressed forwardlooking statements investors understand possible predict identify factors consider risks described item complete statement potential risks anduncertainties company undertake publicly update forwardlooking statement may made time time whether result new information future events developmentspart item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's three business segments consumer pharmaceutical medical devices within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business company organized three business segments consumer pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report consumer consumer segment includes broad range products used baby care oral care beauty previously referred skin care overthecounter pharmaceutical womens health wound care markets baby care includes johnsons line products oral care includes listerine product line major brands beauty include aveeno clean clear dabao johnsons adult le petite marseillais neutrogena roc ogx product lines overthecounter medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products pepcid line acid reflux products major brands womens health outside north america stayfree carefree sanitary pads ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines products marketed general public sold retail outlets distributors throughout world pharmaceutical pharmaceutical segment focused five therapeutic areas immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis infectious diseases vaccines eg hiv hepatitis respiratory infections tuberculosis neuroscience eg alzheimer 's disease mood disorders schizophrenia oncology eg prostate cancer hematologic malignancies lung cancer cardiovascular metabolic diseases eg thrombosis diabetes products segment distributed directly retailers wholesalers hospitals health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis stelara ustekinumab treatment adults moderate severe plaque psoriasis active psoriatic arthritis adults moderately severely active crohn 's disease prezista darunavir edurant rilpivirine prezcobixrezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder invega paliperidone extendedrelease tablets treatment schizophrenia schizoaffective disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults invega trinzatrevicta paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months risperdal consta risperidone longacting injection treatment schizophrenia maintenance treatment bipolar disorder adults velcade bortezomib treatment multiple myeloma use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patients previouslyuntreated mantle cell lymphoma zytiga abiraterone acetate used combination prednisone treatment metastatic castrationresistant prostate cancer imbruvica ibrutinib oral oncedaily therapy approved use treating certain bcell malignancies blood cancers waldenstrm 's macroglobulinemia darzalex daratumumab treatment relapsedrefractory multiple myeloma procrit epoetin alfa sold outside us eprex stimulate red blood cell production xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe invokana canagliflozin treatment adults type diabetes invokametvokanamet canagliflozinmetformin hcl combination therapy fixed doses canagliflozin metformin hydrochloride treatment adults type diabetes invokamet xr canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adults type diabetes many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medical devices medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics include orthopaedic products general surgery biosurgical endomechanical energy products electrophysiology products treat cardiovascular disease sterilization disinfection products reduce surgical infection diabetes care products blood glucose monitoring insulin delivery products disposable contact lenses details regarding acquisitions divestitures see note consolidated financial statements included item geographic areas business johnson johnson conducted operating companies located countries including us virtually countries throughout world products made sold international business include many described segments business consumer pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed us subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed significant number patents us countries relating products product uses formulations manufacturing processes aggregate believed material importance company operation businesses companys subsidiaries face patent challenges third parties including challenges seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products significant legal proceedings claims involving company 's patent intellectual property described note legal proceedings intellectual property notes consolidated financial statements included item report sales companys largest product remicade infliximab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company two sets patents related specifically remicade first set patents coowned janssen biotech inc whollyowned subsidiary johnson johnson nyu langone medical center nyu janssen biotech inc exclusive license nyu 's interests patents patents expired countries outside unitedstatesin united states one remaining patent expires september stands rejected following reexamination proceedings instituted third party united states patent trademark office uspto patent also held invalid federal district court district massachusetts decisions uspto federal district court appealed us court appeals federal circuit appeals pending second set patents specifically related remicade granted kennedy institute rheumatology europe canada australia united states janssen biotech inc licenses exclusive human antitnf antibodies semiexclusive nonhuman antitnf antibodies patents expire outside united states united states certain patents successfully challenged invalidated others review various patent offices around world also subject litigation canada company expect extensions available described patents specifically related remicade third party received approval food drug administration sale infliximab biosimilar united states introduced biosimilar us market late extensive description legal matters regarding patents related remicade see note legal proceedings intellectual property pharmaceutical remicade related cases notes consolidated financial statements included item report addition competing immunology market remicade company currently marketing stelara ustekinumab simponi golimumab simponi aria golimumab next generation immunology products remaining patent lives seven years trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration us countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involve significant expenditures advertising promotion research development research activities represent significant part companys businesses research development expenditures relate processes discovering testing developing new products improving existing products well demonstrating product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities amounted billion billion billion fiscal years respectively research facilities located united states belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements change past year expected material effect upon capital expenditures cash flows earnings competitive positionregulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation us drug device cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration fda continues result increases amounts testing documentation required fda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care generally us government agencies continue implement extensive requirements patient protection affordable care act aca positive negative impacts us healthcare industry much remaining uncertain various provisions aca potential modification repeal aca provisions ultimately affect industry regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may affect sourcing supply pricing materials used company 's products processes also subject lengthy regulatory approvals available information companys main corporate website address wwwjnjcom copies companys quarterly reports form q annual report current reports form k filed furnished us securities exchange commission sec amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys sec filings also available companys website wwwinvestorjnjcomseccfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov addition written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance government affairs committee science technology sustainability committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovcfm company 's website provided without charge shareholder submitting written request provided information companys website deemed part report incorporated filings company makes sec item risk factors company faces number uncertainties risks difficult predict many outside company 's control addition information report companys filings sec investors consider carefully factors set forth investors aware possible predict identify factors following meant complete discussion potential risks uncertainties known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected potentially material wayone companys key products remicade infliximab experiencing biosimilar competition result reduction us sales remicade company experienced significant challenges patents covering largest product remicade infliximab accounting approximately companys total revenues fiscal continues assert certain patents related product april fda approved sale united states infliximab biosimilar marketed subsidiary pfizer inc october notice launch period us biologics price competition innovation act bpcia passed november pfizer began shipment infliximab biosimilar wholesalers united states sales infliximab biosimilar us market result reduction us sales remicade global sales companys pharmaceutical medical devices segments may negatively impacted healthcare reforms increasing pricing pressures sales companys pharmaceutical medical device products significantly affected reimbursements thirdparty payers government healthcare programs private insurance plans managed care organizations part various efforts contain healthcare costs payers putting downward pressure prices products reimbursed united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries part due continued consolidation among health care providers could result pricing pressures outside united states numerous major markets including eu japan pervasive government involvement funding healthcare regard directly indirectly impose price controls limit access reimbursement companys products reduce value intellectual property protection company subject significant legal proceedings result significant expenses fines reputational damage ordinary course business johnson johnson subsidiaries subject numerous claims lawsuits involving various issues patent disputes product liability claims product sales marketing pricing practices violate various antitrust unfair trade practices andor consumer protection laws significant proceedings described note legal proceedings notes consolidated financial statements included item report company believes substantial defenses matters feasible predict ultimate outcome litigation company could future required pay significant amounts result settlements judgments matters potentially excess accruals resolution increase accruals one matters reporting period could material adverse effect company 's results operations cash flows period furthermore result cost availability factors effective november company ceased purchasing thirdparty product liability insurance product reliability safety effectiveness concerns significant negative impacts sales results operations lead litigation cause reputational damage concerns product safety whether raised internally regulators consumer advocates whether based scientific evidence result safety alerts product recalls governmental investigations regulatory action part fda counterpart countries private claims lawsuits payment fines settlements declining sales reputational damage circumstances also result damage brand image brand equity consumer trust companys products product recalls past could future prompt government investigations inspections shutdown manufacturing facilities continued product shortages related sales declines significant remediation costs reputational damage possible civil penalties criminal prosecution changes tax laws exposures additional tax liabilities could negatively impact companys operating results changes tax laws regulations including tax reform proposals us belgium switzerland could negatively impact companys effective tax rate results operations change statutory tax rate may result revaluation companys deferred tax assets liabilities related relevant jurisdiction period new tax law enacted potentially resulting material expense benefit recorded companys consolidated statement earnings period discussion risks changes tax rates countries including belgium please see managements discussion analysis results operations financial conditionother informationeconomic market factors item report company conducts business files tax returns numerous countries currently tax audits progress many tax authorities connection organization economic cooperation development base erosion profit shifting beps project starting companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company regularlyassesses likely outcomes tax audits determine appropriateness tax reserves however tax authority could take position tax treatment contrary companys expectations could result tax liabilities excess reserves company may able successfully secure defend intellectual property rights essential companys businesses company owns licenses significant number patents proprietary rights determined patent offices courts lawmakers various countries relating products manufacturing processes rights essential companys businesses materially important companys results operations public policy within outside us become increasingly unfavorable toward intellectual property rights company certain obtain adequate patent protection new products technologies us important markets protections granted last long originally anticipated competitors routinely challenge validity extent companys owned licensed patents proprietary rights litigation interferences oppositions proceedings proceedings absorb resources protracted well unpredictable addition challenges companys products infringe patents third parties could result need pay past damages future royalties adversely affect competitive position sales products question company faced increasing patent challenges third parties seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products united states manufacturers generic versions innovative human pharmaceutical products may challenge validity claim noninfringement innovator products abbreviated new drug application anda process fda bpcia enacted created new regulatory pathway approval fda biosimilar alternatives innovatordeveloped biological products also created mechanisms biosimilar applicants challenge patents innovator biologics inter partes review ipr process uspto created america invents act also used competitors challenge patents held companys subsidiaries example key patent zytiga currently subject patent litigation several ipr proceedings brought generic companies seeking invalidate patent event company successful defending patents challenges upon atrisk launch despite pending patent infringement litigation generic biosimilar firm product company lose major portion revenues referenced product short period time current legal proceedings involving companys patents intellectual property rights described note legal proceedingsintellectual property notes consolidated financial statements included item report companys businesses operate highly competitive product markets competitive pressures could adversely affect companys earnings company faces substantial competition three operating segments geographic markets companys businesses compete companies sizes basis costeffectiveness technological innovations intellectual property rights product performance real perceived product advantages pricing availability rate reimbursement company also competes market participants securing rights acquisitions collaborations licensing agreements third parties competition rights product candidates technologies may result significant investment acquisition costs onerous agreement terms company competitors development effective less costly products andor ability secure patent intellectual property rights successfully market products ahead us could negatively impact sales companys existing products well ability bring new products market despite significant prior investment related product development companys pharmaceutical businesses loss patent exclusivity product often followed substantial reduction sales competitors gain regulatory approval generic competing products enter market similar competition triggered loss exclusivity biological product companys medical device businesses technological innovation product quality reputation customer service especially important competitiveness development companies new improved products processes technologies could threaten make companys products technologies less desirable less economical obsolete companys consumer businesses face intense competition branded products retailers privatelabel brands company fails sufficiently differentiate market brand name consumer products could adversely affect revenues profitability productssignificant challenges delays companys innovation development new products technologies indications could adverse impact companys longterm success companys continued growth success depends ability innovate develop new differentiated products services address evolving health care needs patients providers consumers development successful products technologies also necessary offset revenue losses companys existing products lose market share due various factors competition loss patent exclusivity new products introduced within past five years accounted approximately sales company certain whether able develop license otherwise acquire companies products technologies whether particular product candidates granted regulatory approval approved whether products commercially successful company pursues product development internal research development well collaborations acquisitions joint ventures licensing arrangements third parties contexts developing new products particularly pharmaceutical biotechnology products medical devices requires significant investment resources many years biopharmaceutical research development programs result commercially viable products process depends many factors including ability discern patients health care providers future needs develop promising new compounds strategies technologies achieve successful clinical trial results secure effective intellectual property protection obtain regulatory approvals timely basis reach market successfully differentiate companys products competing products approaches treatment new products enhancements existing products may accepted quickly significantly marketplace due product price competition changes customer preferences healthcare purchasing patterns resistance healthcare providers uncertainty thirdparty reimbursement even following initial regulatory approval success product adversely impacted safety efficacy findings larger real world patient populations well market entry competitive products company faces increasing regulatory scrutiny imposes significant compliance costs exposes company government investigations legal actions penalties like companies healthcare industry company subject extensive regulation investigations legal action national state local government agencies united states countries operate regulatory issues regarding compliance good manufacturing practices cgmp comparable quality regulations foreign countries manufacturers drugs devices consumer products lead fines penalties product recalls product shortages interruptions production delays new product approvals litigation addition marketing pricing sale companys products subject regulation investigations legal actions including federal food drug cosmetic act medicaid rebate program federal state false claims acts state unfair trade practices acts consumer protection laws increased scrutiny health care industry business practices recent years government agencies state attorneys general us resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment participation government healthcare programs debarment could material adverse effect companys business results operations significant current investigations litigation brought government agencies described note legal proceedingsgovernment proceedings notes consolidated financial statements included item report company faces variety risks associated conducting business internationally companys extensive operations business activity outside us accompanied certain financial economic political risks including listed foreign currency exchange fiscal approximately companys sales occurred outside us approximately europe western hemisphere excluding us asiapacific africa region changes nonus currencies relative us dollar impact companys revenues expenses company uses financial instruments mitigate impact fluctuations currency exchange rates cash flows unhedged exposures continue subject currency fluctuations addition weakening strengthening us dollar may result significant favorable unfavorable translation effects operating results companys nonus business activity translated us dollars inflation currency devaluation risks company faces challenges maintaining profitability operations economies experiencing high inflation rates company accounted operations venezuela highly inflationary prior threeyear cumulative inflation rate surpassed company strives maintain profit margins areas cost reduction programs productivity improvements periodic price increases might experience operating losses result continued inflation addition impact currency devaluations countries experiencing high inflationrates significant currency exchange fluctuations could negatively impact companys operating results illegal importation pharmaceutical products illegal importation pharmaceutical products countries government price controls market dynamics result lower prices may adversely affect companys sales profitability us countries company operates exception limited quantities prescription drugs personal use foreign imports pharmaceutical products illegal current us law however volume illegal imports continues rise ability patients customers obtain lowerpriced imports grown significantly antibribery regulations company subject various federal foreign laws govern international business practices respect payments government officials laws include us foreign corrupt practices act fcpa prohibits us publicly traded companies promising offering giving anything value foreign officials corrupt intent influencing foreign official purpose helping company obtain retain business gain improper advantage companys business heavily regulated therefore involves significant interaction foreign officials also many countries outside us health care providers prescribe human pharmaceuticals employed government purchasers human pharmaceuticals government entities therefore companys interactions prescribers purchasers subject regulation fcpa addition us application enforcement fcpa various jurisdictions company operates laws regulations including uk bribery act aimed preventing penalizing corrupt anticompetitive behavior enforcement activities laws could subject company additional administrative legal proceedings actions could include claims civil penalties criminal sanctions administrative remedies including exclusion health care programs legal social political risks risks inherent conducting business globally include protective economic policies taken governments trade protection measures importexport licensing requirements compliance local regulations laws including countries regulatory requirements restricting companys ability manufacture sell products relevant market diminished protection intellectual property contractual rights certain jurisdictions potential nationalization expropriation companys foreign assets disruptions markets due war armed conflict terrorism social upheavals pandemics interruptions delays manufacturing operations could adversely affect companys business sales reputation companys manufacture products requires timely delivery sufficient amounts complex highquality components materials subsidiaries operate manufacturing facilities well sourcing hundreds suppliers around world company past may future face unanticipated interruptions delays manufacturing internal external supply chain manufacturing disruptions occur many reasons including regulatory action production quality deviations safety issues labor disputes sitespecific incidents fires natural disasters raw material shortages political unrest terrorist attacks delays difficulties manufacturing result product shortages declines sales reputational impact well significant remediation related costs associated addressing shortage information security incident including cybersecurity breach could negative impact companys business reputation meet business objectives company relies internal information technology systems networks third parties vendors process store sensitive data including confidential research business plans financial information intellectual property personal data extensive information security cybersecurity threats affect companies globally pose risk security availability systems networks confidentiality integrity availability companys sensitive data company continually assesses threats makes investments increase internal protection detection response capabilities well ensure companys third party providers required capabilities controls address risk date company experienced material impact business operations resulting information cybersecurity attacks however frequently changing attack techniques along increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory actionitem b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer pharmaceutical medical devices worldwide total within united states seven facilities used consumer segment seven pharmaceutical segment medical devices segment outside united states facilities used consumer segment pharmaceutical segment medical devices segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world research facilities also discussed item report business research development company 's subsidiaries generally seek manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition repair facilities well utilized mcneilppc inc johnson johnson consumer inc mcneilppc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree fort washington facility voluntarily shut april subsequently many products transferred manufacturing sites successfully reintroduced market mcneilppc successfully completed requirements contained consent decree workplans lancaster las piedras manufacturing sites completed steps required thirdparty certification fort washington plant thirdparty cgmp expert submitted written certifications fda three manufacturing sites following fda inspections mcneilppc received notifications fda three manufacturing facilities conformity applicable laws regulations commercial production fort washington started september consent decree receiving notice fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thus thirdparty expert continue reassess sites various times least five years discussion legal proceedings related thismatter found note legal proceedings government proceedings mcneil consumer healthcare notes consolidated financial statements included item report information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements included item report segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements included item report item legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report addition johnson johnson subsidiaries time time party government investigations inspections proceedings relating environmental matters including compliance applicable environmental laws item mine safety disclosures applicable executive officers registrant listed executive officers company family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky incorporated herein reference material captioned item election directors proxy statement name age position dominic j caruso member executive committee executive vice president chief financial officera joaquin duato member executive committee executive vice president worldwide chairman pharmaceuticalsb peter fasolo member executive committee executive vice president chief human resources officerc alex gorsky chairman board directors chairman executive committee chief executive officer jorge mesquita member executive committee executive vice president worldwide chairman consumerd sandra e peterson member executive committee executive vice president group worldwide chairmane gary pruden member executive committee executive vice president worldwide chairman medical devicesf paulus stoffels member executive committee executive vice president chief scientific officerg michael h ullmann member executive committee executive vice president general counselh mr j caruso joined company company acquired centocor inc time acquisition senior vice president finance centocor mr caruso named vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance companys medical devices diagnostics group mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer april named executive vice president chieffinancial officer b mr j duato joined company janssenfarmaceutica sa spain became managing director janssencilag spa italy led ortho biotech europe relocating united states serve vice president president ortho biotech inc named company group chairman orthoclinical diagnostics company group chairman pharmaceuticals oversaw pharmaceutical product launches major therapeutic franchises canada united states latin america named worldwide chairman pharmaceuticals responsible global commercial businesses janssen pharmaceutical companies including functional support research development organizations april mr duato became member executive committee named executive vice president worldwide chairman pharmaceuticals c dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee april named executive vice president chief human resources officer mr j mesquita joined company worldwide chairman consumer prior joining company served various marketing leadership capacities across latin america including roles oral care beauty procter gamble company april mr mesquita became member executive committee named executive vice president worldwide chairman consumer e ms e peterson joined company group worldwide chairman member executive committee oversees consumer consumer medical device businesses company 's operating infrastructure supply chain information technology global services health wellness global design health technology prior joining company ms peterson chairman chief executive officer bayer cropscience ag germany previously serving president chief executive officer bayer medical care president bayer healthcare ag 's diabetes care division joining bayer ms peterson held number leadership roles medco health solutions previously known merckmedco april ms peterson named executive vice president group worldwide chairman johnson johnson effective june ms peterson assume leadership hospital medical device business addition current responsibilities f mr g pruden joined company janssen pharmaceuticainc held number senior positions sales marketing strategic account management april became president janssenortho inc canada january mr pruden appointed worldwide president ethicon products became company group chairman ethicon named worldwide chairman global surgery group worldwide chairman medical devices april mr pruden became member executive committee named executive vice president worldwide chairman medical devices mr pruden announced intention retire company effective june g dr p stoffels joined company acquisition tibotec virco nv chief executive officer virco nv chairman tibotec nv appointed company group chairman global virology assumed role company group chairman pharmaceuticals responsibility worldwide research development central nervous system internal medicine franchises dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals responsibility company 's therapeutic pipeline global research development strategic business development dr stoffels also appointed chief scientific officer responsibility enterprisewide innovation product safety member executive committee april dr stoffels named executive vice president chief scientific officer h mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics appointed vice president general counsel member executive committee april mr ullmann named executive vice president general counsel part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report item managements discussion analysis results operations financial condition liquidity capital resources dividends information common stock market prices note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities october company announced board directors approved share repurchase program authorizing company purchase billion company 's common stock share repurchases take place open market time time based market conditions repurchase program time limit may delayed suspended periods discontinued time following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar purchased value shares total number part publicly units may yet shares avg price announced plans purchased period purchased paid per share programs plans programs october october october november november january total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions shares purchased pursuant repurchase program publicly announced october shares purchased openmarket transactions part systematic plan meet needs companys compensation programs january aggregate shares purchased total billion since inception repurchase program announced october january maximum number shares may yet purchased plan based closing price johnson johnson common stock new york stock exchange december per share item selected financial data summary operations statistical data dollars millions except per share amounts sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands attributable johnson johnson amounts reclassified conform current year presentation item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care beauty previously referred skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives company manages within strategic framework credo foundation company believes strategic operating principles broadly based human health care managing business long term decentralized management approach committed people values crucial successfully meeting demands rapidly evolving markets compete end management focused longterm strategic growth drivers creating value innovation expanding global reach local focus excellence execution leading purpose company broadly based human health care committed creating value developing accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion sales invested research development reflecting managements commitment delivering new differentiated products services meet evolving health care needs sustain companys longterm growth diverse businesses operating companies located countries key drivers companys success maintaining companys decentralized management approach time leveraging extensive resources enterprise positions company well innovate execute strategic plans reach markets globally well address needs challenges local markets order remain leader health care company strives maintain purposedriven organization committed developing global business leaders achieve growth objectives businesses managed longterm order sustain market leadership positions enable growth provides enduring source value shareholders credo unifies johnson johnson employees achieving objectives provides common set values serve foundation companys responsibilities patients consumers health care professionals employees communities shareholders company believes foundational values strategic framework longterm growth drivers along overall mission improving quality life people around world enable johnson johnson continue leader health care industryresults operations analysis consolidated sales worldwide sales increased billion compared decrease increase sales changes consisted following sales increasedecrease due volume price currency total acquisitions divestitures negative impact worldwide operational sales growth competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir negative impact worldwide operational sales growth operations venezuela negatively impacted worldwide operational sales growth introduction competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir negative impact worldwide operational sales growth impact acquisitions divestitures worldwide operational sales growth negative sales company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positive impact divestiture orthoclinical diagnostics business negative impact worldwide operational growth sales us companies billion billion billion represents increases sales international companies billion billion billion represents decreases increase fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe experienced decline compared prior year including operational growth offset negative currency impact sales companies western hemisphere excluding us experienced decline compared prior year including operational growth offset negative currency impact sales companies asiapacific africa region achieved growth compared prior year including operational growth positive currency impact sales growth percentage compared prior year negatively impacted approximately additional shipping days see note consolidated financial statements annual closing date details additional week added days sales also added full week 's worth operating costs therefore net earnings impact negligible company two wholesalers distributing products three segments represented approximately total consolidated revenues company one wholesaler distributing products three segments represented approximately respectively total consolidated revenues analysis sales business segments consumer segment consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion increase international sales billion decrease included operational growth offset negative currency impact impact acquisitions divestitures consumer segment operational sales growth negative consumer segment operational sales growth negatively impacted operations venezuela negatively impacted due additional shipping days major consumer franchise sales change dollars millions vs vs otc beauty baby care oral care womens health wound careother total consumer sales prior year amounts reclassified conform current year product disclosure formerly skin care overthecounter otc franchise sales billion increased compared prior year included operational growth negative currency impact operational growth primarily driven analgesics antismoking aids digestive health products beauty franchise sales billion increased compared prior year included operational growth negative currency impact operational growth primarily due sales recent acquisitions vogue international llc contributed approximately neostrata company inc well sales growth neutrogena aveeno adultproducts dabao products baby care franchise sales billion decrease compared prior year primarily due competitive pressure partially offset sales growth aveeno babyproducts oral care franchise sales billion decrease compared prior year included operational growth negative currency impact operational growth driven increased sales listerine productsattributable new product launches successful marketing campaigns womens health franchise sales billion decrease compared prior year primarily due operations venezuela us divestiture tucks wound careother franchise sales billion decrease primarily due splenda divestiture consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion increase international sales billion decrease included operational growth offset negative currency impact divestitures negative impact worldwide consumer segment operational growth pharmaceutical segment pharmaceutical segment sales billion increase included operational growth partially offset negative currency impact us sales billion increase international sales billion increase included operational growth partially offset negative currency impact acquisitions divestitures competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir negative impact operational growth pharmaceutical segment pharmaceutical segment operational growth negatively impacted due additional shipping days pharmaceutical segment operational growth compared prior year impacted adjustments previous reserve estimates periods included approximately billion adjustments major pharmaceutical therapeutic area sales change vs vs dollars millions total immunology remicade simponisimponi aria stelara immunology total infectious diseases edurantrilpivirine olysiosovriad prezista prezcobixrezolsta infectious diseases total neuroscience concertamethylphenidate invegapaliperidone invega sustennaxepliontrinza risperdal consta neuroscience total oncology darzalex imbruvica velcade zytiga oncology cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sales prior year amounts reclassified conform current year presentation percentage greater immunology products achieved sales billion representing increase compared prior year immunology products growth included operational growth negative currency impact strong growth remicadeinfliximab stelara ustekinumab simponisimponi aria golimumabwas primarily driven immunology market growth increased penetration stelara ustekinumab simponisimponi aria golimumab patents remicadeinfliximabin certain countries europe expired february biosimilar versions remicade introduced certain markets outside united states resulting reduction sales remicade markets additional biosimilar competition likely result reduction remicade sales markets outside united states introduction biosimilar version remicade united states subject enforcement patent rights approval us food drug administration fda compliance day notice provisions biologics price competition innovation act bpcia april fda approved sale united states infliximab biosimilar marketed subsidiary pfizer inc october period notice launch bpcia passed pfizer inc began shipment infliximab biosimilar wholesalers united states late november sales infliximab biosimilar us market result reduction us sales remicade company continues assert remicade related patent rights see note consolidated financial statements description legal matters regarding remicade patents infectious disease products sales billion decline included operational decrease negative currency impact competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir significant negative impact sales decline hepatitis c sales partially offset sales growth edurantrilpivirine prezcobixdarunavircobicistat neuroscience products sales billion decrease included operational decrease negative currency impact strong sales invega sustennaxeplion trinzapaliperidone palmitate offset lower sales invega paliperidone due generic competition risperdal consta risperidone impact divestitures sales growth concertamethylphenidate primarily due therapeutic equivalence reclassification generic competitors oncology products achieved sales billion representing increase compared prior year oncology products growth included operational growth negative currency impact contributors growth oncology products strong sales imbruvica ibrutinib darzalex daratumumab due patient uptake additional country launches additional indications imbruvica generic competition negatively impacted sales growth velcadebortezomib sales growth zytiga abiraterone acetate asia pacific region primarily due launch china earlier year partially offset lower sales europe due competition cardiovascularmetabolismother products sales billion decline included operational increase negative currency impact contributors growth strong sales xareltorivaroxaban due market share growth invokanainvokamet canagliflozin due market growth continued uptake european union canada sales hormonal contraceptives negatively impacted generic competition higher adjustment previous reserve estimates compared negatively impacted cardiovascularmetabolismother approximately company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows product name chemical us eu us eu name indication approv approv filing filing combination lenalidomide dexamethasone bortezomib dexamethasone treatment patients multiple myeloma received darzalex daratumumab least one prior therapy treatment double refractory multiple myeloma single tablet regimen hiv treatment naive patients darunavir str treatment experienced patients treatment adults living moderate severe guselkumab plaque psoriasis additional indication firstline treatment chronic imbruvica ibrutinib lymphocytic leukemia expanded label include overall survival combination data chronic lymphocytic leukemiasmall lymphocytic lymphoma cllsll expanded label include treatment patients relapsed refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma combination bendamustine rituximab invokamet canagliflozininitial therapy fdc metformin immediate release oncedaily therapy combining fixed doses invokamet xr canagliflozin metformin hydrochloride extended canagliflozin release treatment adults type diabetes simponi golimumab treatment polyarticular juvenile idiopathic arthritis treatment adults living active psoriatic arthritis treatment adults living active ankylosing simponi aria golimumab spondylitis sirukumab treatment rheumatoid arthritis treatment adults moderately severely active stelara ustekinumab crohn 's disease treatment adolescents years age moderate severe plaque psoriasis trevicta paliperidone palmitate monthly injection maintenance treatment schizophrenia adult patients pharmaceutical segment sales billion decrease included operational growth offset negative currency impact us sales billion increase international sales billion decrease included operational growth offset negative currency impact pharmaceutical segment operational growth negatively impacted due introduction competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positively impacted due adjustment previous reserve estimates including managed medicaid rebates primarily cardiovascularmetabolismother therapeutic area divestitures negative impact worldwide pharmaceutical segment operational growthmedical devices segment medical devices segment sales billion decrease included operational increase negative currency impact us sales billion increase compared prior year international sales billion decrease compared prior year operational increase negative currency impact acquisitions divestitures negative impact worldwide operational growth medical devices segment compared medical devices segment operational growth negatively impacted due additional shipping days major medical devices franchise sales change dollars millions vs vs orthopaedics hips knees trauma spine surgery advanced general specialty vision care cardiovascular diabetes care diagnostics total medical devices sales june company divested orthoclinical diagnostics business diagnostics franchise orthopaedics franchise sales billion increase included operational growth negative currency impact sales growth primarily driven market growth us sales trauma tfna nailing system worldwide sales hip primary stem platform attune knee system growth negatively impacted continued pricing pressures surgery franchise sales billion increase included operational growth negative currency impact operational growth advanced surgery driven endocutter energy biosurgery products primarily attributable market growth increased penetration certain markets new product launches acquisition neuwave medical inc also contributed growth operational decline general surgery due lower sales women 's health urology products pricing pressures partially offset growth sutures operational decline specialty surgery primarily due lower sales acclarent products advanced sterilization products outside us divestitures competitive pressures sterilmed partially offset growth mentor products outside us vision care franchise achieved sales billion increase included operational growth positive currency impact growth major regions primarily driven new product launches cardiovascular franchise sales billion decrease represented operational decline strong operational growth electrophysiology business driven market growth share growth new product launches offset impact divesting cordis business company completed divestiture cordis business cardinal health october additional details see note consolidated financial statements diabetes care franchise sales billion decrease represented operational decline negative currency impact operational decline primarily due price declines andcompetitive pressures january subsequent yearend company announced engaging process evaluate potential strategic options diabetes care franchise medical devices segment sales billion decrease included operational decline negative currency impact us sales billion decrease compared prior year international sales billion decrease compared prior year operational decrease negative currency impact divestitures orthoclinical diagnostics cordis businesses negative impact respectively worldwide operational growth medical devices segment compared analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion compared billion increase increase primarily attributable higher sales volume favorable mix business lower selling marketing administrative costs partially offset higher net litigation expense billion higher restructuring charge billion compared additionally fiscal year included higher gains sale assetsbusinesses compared fiscal year included gains billion divestitures controlled substance raw material api business certain anesthetic products europe certain nonstrategic consumer brands versus gains billion recorded primarily divestiture cordis business us divestiture nucynta andthe splenda brand partially offset billion intangible asset writedown related acclarent included consolidated earnings provision taxes income decreased billion compared billion decrease decrease primarily attributable significantly lower sales olysiosovriad simeprevir negative currency impacts restructuring charge billion higher intangible asset writedowns billion compared decrease partially offset lower net litigation expense billion lower synthes integration costs billion positive adjustment billion previous reserve estimates including managed medicaid rebates higher gains billion divestitures compared prior year fiscal year included higher gains billion primarily divestitures cordis business splenda brand us divestiture nucynta versus gains recorded divestitures orthoclinical diagnostics business ky brand additionally included additional year branded prescription drug fee billion percent sales consolidated earnings provision taxes income versus cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point increasedecrease prior year selling marketing administrative expenses percent point increasedecrease prior year cost products sold percent sales decreased compared period year ago favorable mix business cost improvement programs partially offset unfavorable impact transactional currency intangible asset amortization expense billion included cost products sold decrease percent sales selling marketing administrative expenses compared prior year primarily due cost management segments favorable mix cost products sold percent sales increased slightly compared prior year favorable mix segments offset million associated restructuring activity medical devices segment negative transactional currency lower sales olysiosovriad simeprevir intangible asset amortization expense included cost products sold billion billion respectively increase percent sales selling marketing administrative expenses compared prior year primarily due incremental investment spending segments impact lower sales olysiosovriad simeprevir partially offset favorable mix inclusion additional year branded prescription drug fee billion research development expense research development expense segment business follows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities increased compared decreased percent sales decrease percent sales attributable higher overall sales pharmaceutical segment increased dollar spend pharmaceutical segment investment spending advance pipeline worldwide costs research development activities increased compared increase percent sales attributable increased investment spending primarily pharmaceutical segment lower overall sales business mix inprocess research development iprd company recorded iprd charge million discontinuation development program related crucell company recorded iprd charge billion primarily discontinuation certain development projects related covagen company recorded iprd charge billion impairment various iprd projects related respivert crucell mentor synthes delay discontinuation certain development projects income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc jjdc gains losses divestitures transactional currency gains losses acquisitionrelated costs litigation accruals settlements well royalty income change income expense net fiscal year unfavorable change billion compared prior year primarily due higher gains sale assetsbusinesses fiscal year compared fiscal year included gains billion divestitures controlled substance raw material api business certain anesthetic products europe certain nonstrategic consumer brands versus gains billion recorded primarily divestiture cordis business us divestiture nucynta andthe splenda brand additionally fiscal year included higher litigation expense billion compared partially offset billion intangible asset writedown related acclarent included fiscal year change income expense net fiscal year favorable change billion compared prior year primarily due lower litigation expense billion lower synthes integration costs billion higher jjdc portfolio gains billion compared prior year additionally fiscal year included higher gains billion primarily divestitures cordis business splenda brand us divestiture nucynta versus gains recorded divestitures orthoclinical diagnostics business ky brand partially offset higher intangible asset writedowns billion interest income expense interest income increased million compared due higher average balance cash cash equivalents marketable securities higher interest rates cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance interest expense higher compared average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion primarily due increased borrowings february may company increased borrowings capitalizing favorable terms capital markets proceeds theborrowings used general corporate purposes primarily stock repurchase program interest income increased million compared due higher average balance cash cash equivalents marketable securities higher interest rates cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase yearend cash balance primarily due cash generated operating activities interest expense increased slightly compared average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion increase commercial paper general corporate purposes primarily stock repurchase program income tax segment income tax segment business follows income tax segment sales percent segment sales dollars millions consumer pharmaceutical medical devices total less expenses allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense general corporate income expense consumer segment consumer segment income tax percent sales versus primarily driven favorable selling marketing administrative expenses due cost management higher gross profit margins cost improvement projects favorable mix partially offset higher gains related divestitures primarily divestiture splenda brand additionally operations venezuela negatively impacted consumer segment income tax compared consumer segment income tax percent sales versus primarily due lower divestiture gains versus consumer segment tax included gain billion divestitures primarily divestiture splenda brand consumer segment included gain billion divestitures primarily divestiture ky brand pharmaceutical segment pharmaceutical segment income tax percent sales versus increase income tax primarily due tostrong sales volume growth favorable selling marketing administrative expenses due cost management additionally fiscal year higher gains billion related divestitures partially offset higher iprd charge billion compared fiscal year included gains divestitures controlled substance raw material api business certain anesthetic products europe versus gains recorded us divestiture nucynta pharmaceutical segment income tax percent sales versus favorable income tax primarily due higher gains recognized partially offset sales decline olysiosovriadsimeprevir increased investment spending negative currency impacts compared included gain billion us divestiture nucyntaas well receipt contingent payment positive adjustment previous reserve estimates including managed medicaid rebates additionally pharmaceutical segment income tax negatively impacted billion additional year branded prescription drug fee higher intangible asset amortization expense billion primarily related writedown incivo telaprevir medical devices segment medical devices segment income tax percent sales versus decrease income tax percent sales primarily due lower gains billion related divestitures higher litigation expense billion higher restructuring charge billion compared partially offset intangible asset writedown billion related acclarent favorable selling marketing administrative expenses medical devices segment income tax percent sales versus primarilydue restructuring charge billion intangible asset writedown billion related acclarent lower gains billion divestitures compared medical devices segment included gains billion primarily divestiture cordis business versus gain billion recorded divestiture orthoclinical diagnostics business income tax favorably impacted lower net litigation expense billion included gain litigation settlement agreement billion guidant lower synthes integration costs billion compared restructuring company announced restructuring actions medical devices segment expected result annualized pretax cost savings million billion majority expected realized end approximately million savings realized savings provide company added flexibility resources fund investment new growth opportunities innovative solutions customers patients company estimates connection plans record pretax restructuring related charges approximately billion billion expected incurred end company recorded pretax charge million million included cost products sold million included income expense company recorded pretax charge million million included cost products sold restructuring charges billion recorded since restructuring announced see note consolidated financial statements additional details related restructuring provision taxes income worldwide effective income tax rate effective tax rate decreased compared described note consolidated financial statements company adopted new accounting standard reporting additional tax benefits sharebased compensation vested exercised fiscal year adoption new standard reduced effective tax rate fiscal versus remainder change effective tax rate primarily related lower earnings taxes united states settlement several uncertain tax positions versus decrease effective tax rate compared primarily attributable increases taxable income lower tax jurisdictions relative higher tax jurisdictions tax benefit resulting restructuring international affiliates additionally effective tax rate affected items mentioned increase effective tax rate compared attributable following divestiture orthoclinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code ii settlement substantially issues related companys us internal revenue service audit tax years liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion increase approximately billion cash generated operating activities offset billion net cash used investing activities billion net cash used financing activities billion due effect exchange rate changes cash cash equivalents addition company billion marketable securities end billion end see note consolidated financial statements additional details cash cash equivalents marketable securities cash flow operations billion result billion net earnings billion noncash expenses adjustments depreciation amortization stockbased compensation assets writedowns reduced billion net gains sale assetsbusinesses billion related deferred taxes billion related accounts receivable inventories current noncurrent liabilities additional sources operating cash flow billion resulted increase accounts payable accrued liabilities decrease current noncurrent assets investing activities use billion primarily acquisitions net cash acquired billion additions property plant equipment billion partially offset proceeds net sale investments primarily marketable securities billion billion proceeds disposal assetsbusinesses financing activities use billion primarily dividends shareholders billion billion repurchase common stock financing activities also included source billion net proceeds short longterm debt billion proceeds stock options exercisedemployee withholding tax stock awards net company announced definitive agreement acquire abbott medical optics inc approximately billion january subsequent year end company announced definitive transaction agreement acquire actelion ltd approximately billion abbott medical optics closed february company use cashheld company 's foreign subsidiaries pay acquisitions october company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock january billion repurchased program repurchase program time limit may delayed suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash access capital markets previous share repurchase program approved july authorizing company purchase billion company 's shares common stock completed april company continued access liquidity commercial paper market company shelf registration us securities exchange commission expired february company plans file new shelf registration february enable issue debt securities timely basis additional details borrowings see note consolidated financial statements company anticipates operating cash flows existing credit facilities access capital markets provide sufficient resources fund operating needs concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion january billion january approximately billion january approximately billion january southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices local affiliates total net trade accounts receivable balance customers approximately billion january billion january company continues receive payments customers cases late payments interest customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar january market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities approximately millionthe company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material total borrowings end billion billion respectively increase borrowings result financing company 's share repurchase program general corporate purposes net cash cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend increase summary borrowings found note consolidated financial statements contractual obligations commitments companys contractual obligations primarily leases debt unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities january see notes consolidated financial statements details interest unfunded debt debt retirement operating dollars millions obligations obligations plans leases total total tax matters see note consolidated financial statements retirement plan postemployment medical benefit information see note consolidated financial statements table include activity related business combinations dividends company increased dividend th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular quarterly cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaapthe preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid rebate provision estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers arrangements evaluated determine appropriate amounts deferred recorded reduction revenue addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative selling price upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended january january consumer segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset pharmaceutical segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset includes adjustments medical devices segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position january january cumulative amounts undistributed international earnings approximately billion billion respectively january january company 's foreign subsidiaries held balances cash cash equivalents marketable securities amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated additionally company records insurance receivable amounts thirdparty insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected thirdpartyinsurers company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases health care cost trend rates attrition rates see note consolidated financial statements details rates effect rate change health care cost trend would companys results operations stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield performance share units fair market value calculated three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted january economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period united states weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations venezuela highly inflationary prior threeyear cumulative inflation rate surpassed face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases venezuelan government established alternative systems offerings various foreign currency exchanges fourth quarter number companys transactions conducted official rate declined prior quarters result company determined longer likely outstanding net monetary assets would settled official government rate bolivares fuertes one us dollar therefore company recorded charge million revalue net monetary assets venezuela one governments alternative exchange rates simadi impair nonmonetary assets revaluation january companys venezuelan subsidiaries represented less company 's consolidated assets liabilities company continues business greece company closely monitors economic situation january companys greek subsidiaries represented company 's consolidated assets revenues respectively june united kingdom uk held referendum voters approved exit european union eu commonly referred brexit given lack comparable precedent unclear financial trade regulatory legal implications withdrawal uk eu brexit creates global political economic uncertainty may cause among consequences volatility exchange rates interest rates additional cost containment thirdparty payors changes regulations however company currently believe related effects material impact companys consolidated financial position operating results asof january business companys uk subsidiaries represented less companys consolidated assets fiscal twelve months revenues company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately million income million governments around world including united states consider various proposals make changes tax laws may include increasing decreasing existing statutory tax rates change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted belgian government currently considering proposed change corporate tax code including proposal lower statutory tax rate enacted proposed change would result revaluation company 's deferred tax assets corresponding charge tax expense may material effect companys results operations period based deferred tax asset balances january company estimates every statutory tax lowered additional onetime tax expense approximately million significant portion deferred tax asset described international rd capitalized tax note consolidated financial statements related companys operations belgium us government currently considering various proposals changes corporate tax code proposals include limited lowering statutory tax rate rules international income earned company taxed us impact proposals may material effect companys results operations period future periods belgian us governments still considering proposals certain enacted company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place information see discussion remicade related cases litigation filers abbreviated new drug applications note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated company accrued certain litigation matters continues monitor related legal issue adjust accruals new information developments accordance accounting standards codification asc litigation regulatory matters currently disclosed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions ability make estimates judgments affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cashflows period see note consolidated financial statements information regarding legal proceedings common stock market prices companys common stock listed new york stock exchange symbol jnj february record holders common stock company composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion analysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item report item financial statements supplementary data index audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting johnson johnson subsidiaries consolidated balance sheets january january dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings net earnings per share notes basic diluted cash dividends per share average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service credit cost net amortization gain loss net amortization effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years ended respectively securities million million million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated common stock treasury retained comprehensive issued stock total earnings income amount amount balance december net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january see notes consolidated financial statements johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation venezuela adjustments asset writedowns net gain sale assetsbusinesses deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increase accounts receivable increase inventories increase accounts payable accrued liabilities decrease current noncurrent assets decreaseincrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsemployee withholding tax stock awards net net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds employee withholding tax stock awards conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions see notes consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care beauty previously referred skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics new accounting pronouncements recently adopted accounting pronouncements fiscal first quarter financial accounting standards board fasb issued accounting standards update compensation stock compensation improvements employee share based payment accounting amendments update effective annual periods beginning december interim periods within annual periods early adoption permitted entity interim annual period fiscal second quarter company elected early adopt standard update requires following changes presentation financial statements excess tax benefits deficiencies recognized reduction increase provision taxes income previously company recorded benefits directly retained earnings tax benefit company million fiscal year standard permit retroactive presentation benefit prior fiscal years consolidated statement earnings tax benefit deficiency required classified presented cash flow tofrom operating activities previously required presented cash flow tofrom financing activities consolidated statement cash flows permitted standard company elected adopt reclassification prospective basis therefore prior fiscal years consolidated statement cash flows recast provision clarifies cash payments made taxing authorities employees sharebased compensation classified cash outflow financing activities reclassification required recast retrospectively result fiscal year million classified cash outflow financing activities million million cash outflow reclassified operating activity financing activity proceeds exercise stock optionsemployee withholding tax stock awards net fiscal years respectively diluted net earnings per share calculation applying treasury stock method shares could repurchased assumed proceeds longer include amount excess tax benefit material impact company 's diluted net earnings per share calculation fiscal second quarter fasb issued accounting standards update simplifying presentation debt issuance costs update requires capitalized debt issuance costs presented reduction carrying value debt instead classified deferred charge update effective company annual interim periods beginning december required applied retroactively periods presented update material impact presentation companys financial positionduring fiscal third quarter fasb issued accounting standards update business combinations simplifying accounting measurementperiod adjustments amendments update require acquirer recognize adjustments provisional amounts identified measurement period reporting period adjustment amounts determined update effective company annual interim periods beginning december amendments update applied prospectively adjustments provisional amounts occur effective date update earlier application permitted financial statements issued update material impact companys consolidated financial statements fiscal third quarter fasb issued accounting standards update disclosure uncertainties entitys ability continue going concern standard requires management evaluate annual interim reporting period whether conditions events considered aggregate raise substantial doubt entitys ability continue going concern within one year date financial statements issued available issued substantial doubt raised additional disclosures around managements plan alleviate doubts required update becomes effective annual periods interim reporting periods ending december adoption standard impact companys current disclosures financial statements recently issued accounting pronouncements adopted january fiscal first quarter fasb issued accounting standard update clarifying definition business update narrows definition business providing screen determine integrated set assets activities business screen specifies integrated set assets activities business substantially fair value gross assets acquired disposed concentrated single group similar identifiable assets update effective company annual periods beginning december including interim periods within annual periods early adoption permitted update applied prospectively company currently assessing impact future adoption standard financial statements fiscal first quarter fasb issued accounting standard update simplifying test goodwill impairment update simplifies entity required test goodwill impairment goodwill impairment measured amount reporting units carrying value exceeds fair value exceed carrying amount goodwill update effective company annual interim goodwill impairment tests fiscal years beginning december early adoption permitted update applied prospectively company currently assessing impact future adoption standard financial statements fiscal first quarter fasb issued accounting standard update incomegains losses derecognition nonfinancial assets update clarifies scope asset derecognition guidance adds guidance partial sales nonfinancial assets clarifies recognizing gains losses transfer nonfinancial assets contracts noncustomers update effective company annual interim reporting periods beginning december time amendments update revenue contracts customers update allows company choose either full retrospective method modified retrospective method upon adoption company currently assessing impact future adoption standard financial statements fiscal first quarter fasb issued accounting standards update financial instruments recognition measurement financial assets financial liabilities amendments update supersede guidance classify equity securities readily determinable fair values different categories trading available forsale require equity securities measured fair value changes fair value recognized net income standard amends financial reporting providing relevant information entitys equity investments reducing number items recognized comprehensive income update effective company annual periods beginning december interim periods within annual periods company unable estimate impact future adoption standard financial statements depend equity investments adoption date fiscal first quarter fasb issued accounting standards update leases topic update requires recognition lease assets lease liabilities balance sheet lease obligations disclosing key information leasing arrangements update requires recognition lease assets lease liabilities lessees leases classified operating leases current generally accepted accounting principles update effective company annual interim periods beginning december including interim periods within fiscal years early application permitted update required adopted using modified retrospective approach company anticipates operating leases result inthe recognition additional assets corresponding liabilities consolidated balance sheets however expect material impact financial position actual impact depend company 's lease portfolio time adoption company continues toassess implications standard related financial disclosures fiscal first quarter fasb issued accounting standards update investments equity method joint ventures topic simplifying transition equity method accounting amendments update eliminate requirement investment qualifies use equity method result increase level ownership interest degree influence investor must adjust investment results operations retained earnings retroactively step step basis equity method effect previous periods investment held amendments update effective entities fiscal years interim periods within fiscal years beginning december amendments applied prospectively upon effective date increases level ownership interest degree influence result application equity method earlier adoption permitted entity interim annual period adoption standard expected material impact presentation company 's consolidated financial statements fiscal third quarter fasb issued accounting standards update statement cash flows topic classification certain cash receipts cash payments update addresses whether present certain specific cash flow items operating investing financing activities amendments update effective public entities fiscal years interim periods within fiscal years beginning december early adoption permitted including adoption interim period company currently assessing impact future adoption standard consolidated statements cash flows fiscal fourth quarter fasb issued accounting standards update income taxes topic intraentity transfers assets inventory update removes current exception us gaap prohibiting entities recognizing current deferred income tax expenses benefits related transfer assets inventory within consolidated entity current exception defer recognition tax impact transfer inventory within consolidated entity sold third party remains unaffected amendments update effective public entities annual reporting periods beginning december early adoption permitted first interim period entity issues interim financial statements company currently assessing impact future adoption standard consolidated financial statements fiscal second quarter fasb issued accounting standards update simplifying measurement inventory update requires inventory measured lower cost net realizable value net realizable value estimated selling prices ordinary course business less reasonably predictable costs completion disposal transportation update effective company annual interim periods beginning december amendments update applied prospectively earlier application permitted beginning interim annual reporting period update material impact presentation companys financial position fiscal second quarter fasb issued accounting standards update revenue contracts customers along amendments issued replace substantially current us gaap guidance topic eliminate industryspecific guidance early adoption standard permitted original effective date annual periods interim reporting periods beginning december guidance permits two methods adoption full retrospective method retrospective application prior reporting period presented modified retrospective method retrospective application cumulative effect initially applying guidance recognized date initial application providing certain additional disclosures company continues evaluate effect standard preliminarily anticipate material impact financial statements complete assessment impact standard financial statements company continues assess implications standard method adoption related financial disclosures additionally company continues monitor modifications clarifications interpretations issued fasb may affect current conclusions cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily government securities obligations corporate debt securities money market funds reverse repurchase agreements rras rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securities investmentsinvestments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets otherwise classified long term management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary losses securities considered temporary loss recognized earnings property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales returns accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual sales customers fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers arrangements evaluated determine appropriate amounts deferred recorded reduction revenue shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presentedinventories inventories stated lower cost market determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated result cost availability factors effective november company ceased purchasing thirdparty product liability insurance company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion january approximately billion january approximately billion january approximately billion january southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices local affiliates total net trade accounts receivable balance customers approximately billion january billion january company continues receive payments customers cases late payments interest customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessaryresearch development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner milestones capitalized intangible assets amortized cost goods sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position january january cumulative amounts undistributed international earnings approximately billion billion respectively january january company 's foreign subsidiaries held balances cash cash equivalents marketable securities amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liabilityassociated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks therefore includes additional shipping days case case reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end cash cash equivalents current marketable securities comprised dollars millions current carrying unrecognized unrecognized estimated cash cash marketable amount gain loss fair value equivalents securities cash us gov't securities sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits subtotal unrealized gain unrealized loss gov't securities sovereign securities corporate debt securities equity investments subtotal available sale total cash cash equivalents current marketable securities dollars millions current carrying unrecognized unrecognized estimated cash marketable amount gain loss fair value equivalents securities cash us gov't securities sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits subtotal unrealized gain unrealized loss gov't securities sovereign securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale securities reported fair value unrealized gains losses reported net taxes comprehensive income fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs contractual maturities available sale debt securities january follows cost basis fair value dollars millions due within one year due one year five years due five years ten years total debt securities company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end inventories comprised ofdollars millions raw materials supplies goods process finished goods total inventories property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net goodwill january january allocated segment business follows dollars millions consumer pharmaceutical med devices total goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill january goodwill related acquisitions goodwill related divestitures currency translationother goodwill january weighted average amortization periods patents trademarks customer relationships intangible assets years years respectively amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended january january december respectively estimated amortization expense including abbott medical optics amo five succeeding years approximates billion tax per year intangible asset writedowns included income expense net see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings company also uses equity collar contracts manage exposure market risk associated certain equity investments three types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives treated fair value hedges company uses forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features requirements post collateral excluding equity collar contract either company counterparty equity collar contracts company pledged underlying hedged marketable equity securities counterparty collateral ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets liabilities measured fair value contained footnote receivables payables commercial institutions january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps equity collar contracts billion billion billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur gains losses net investment hedges accounted currency translation account ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings income expense net forward foreign exchange contracts cross currency interest rate swaps net investment hedges equity collar contracts interest rate swaps designated fair value hedges hedge ineffectiveness included current period earnings within interest expense current reporting period hedge ineffectiveness associated interest rate swaps material fiscal second quarter company designated euro denominated notes issued may due dates ranging net investment hedge company 's investments certain international subsidiaries use euro functional currency order reduce volatility caused changes exchange rates change carrying value due remeasurement euro notes resulted million pretax gain reflected foreign currency translation adjustment within consolidated statements comprehensive income january balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts net investment hedges equity collar contracts amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity thederivative following table summary activity related derivatives designated cash flow hedges fiscal years ended january january gainloss reclassified gainloss recognized accumulated oci gainloss recognized dollars millions accumulated oci income incomeexpense cash flow hedges income statement caption sales customers cost products sold research development expense interest incomeinterest expense net income expense net total amounts shown table net tax effective portion ineffective portion forward foreign exchange contracts cross currency interest rate swaps includes equity collar contracts fiscal years ended january january loss million loss million respectively recognized income expense net relating forward foreign exchange contracts designated hedging instruments fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company significant financial assets liabilities would require revised valuations standard recognized fair value following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value january january follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts equity collar contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities assets liabilities classified level exception equity investments million classified level includes million million noncurrent assets fiscal years ending january january respectively includes million million noncurrent liabilities fiscal years ending january january respectively includes cross currency interest rate swaps interest rate swaps classified noncurrent assets exception million current assets january carrying amount equity investments million million january january respectively unrealized gains million million january january respectively unrealized losses million million january january respectively classified current marketable securities classified current assets classified accounts payable see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions notes due month libor frn due notes due debentures due notes due debentures due notes due notes due b euro b euro notes due notes due notes due zero coupon convertible subordinated debentures due debentures due notes due notes due notes due notes due b euro debentures due notes due notes due notes due mm euro notes due mm gbp mm gbp notes due notes due mm euro notes due debentures due notes due notes due b euro notes due notes due debentures due debentures due notes due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate january translation rate january excess fair value carrying value debt billion billion fair value longterm debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion borrowed commercial paper program remainder principally represents local borrowing international subsidiaries throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion borrowed commercial paper program remainder principally represents local borrowing international subsidiaries aggregate maturities longterm obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations excluding ireland ireland puerto rico operations research orphan drug tax credits us state local us manufacturing deduction us tax international income additional tax benefits share based compensation us tax benefit assetbusiness disposals effective tax rate company subsidiaries operating puerto rico various tax incentives effective tax rate decreased compared described note company adopted new accounting standard reporting additional tax benefits sharebased compensation vested exercised fiscal year adoption new standard reduced effective tax rate fiscal versus remainder change effective tax rate primarily related lower earnings taxes united states settlement several uncertain tax positions versus decrease effective tax rate compared primarily attributable increases taxable income lower tax jurisdictions relative higher tax jurisdictions tax benefit resulting restructuring international affiliates additionally effective tax rate affected items mentioned increase effective tax rate compared attributable following divestiture orthoclinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code ii settlement substantially issues related companys us internal revenue service audit tax years impact settlement reflected us tax international income line items within reconciliation items noted reflect key drivers rate reconciliationtemporary differences carryforwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international miscellaneous international miscellaneous us total deferred income taxes net valuation allowance related belgium million allowance reversed related deferred tax asset utilized reduce current tax expense company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries realize future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion january recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities irs completed audit tax years currently auditing tax years major jurisdictions company conducts business years remain open generally back year company believes possible audits may completed tax authorities jurisdictions next twelve months however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million respectively total amount accrued interest million million respectively employee related obligations end employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits employees hired january primarily based employees compensation last three five years retirement number years service company announced us defined benefit plan amended adopt new benefit formula effective employees hired january benefits calculated using new formula based employee compensation total years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost credit amortization net transition obligation recognized actuarial losses curtailments settlements net periodic benefit cost amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service credit unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities fiscal year company changed methodology determining service interest cost single weighted average discount rate approach duration specific spot rates along yield curve plans liability cash flows management concluded precise estimate prior change methodology company measured service interest costs utilizing single weightedaverage discount rate derived yield curve used measure plan obligations company accounted change change accounting estimate accordingly accounted prospective basis change impact benefit obligation material impact full year results expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year company offered voluntary lumpsum payment option predetermined threshold certain eligible former employees vested participants us qualified defined benefit pension plan distribution lumpsums substantially completed end fiscal amount distributed approximately million distributions plan material impact companys financial position retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investments cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using net asset value nav provided administrator fund nav based value underlying assets owned fund minus liabilities divided number shares outstanding nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities common stocks valued closing price reported major market individual securities traded substantially common stock classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator nav based value underlying assets owned fund minus liabilities divided number shares outstanding assets level category quoted market price insurance contracts instruments issued insurance companies fair value based negotiated value underlying investments held separate account portfolios well considering credit worthiness issuer underlying investments government assetbacked fixed income securities general insurance contracts classified level quoted prices observable inputs pricing assets assets represented primarily limited partnerships real estate investments well commercial loans commercial mortgages classified corporate debt assets exchange listed actively traded classified level inactively traded assets classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant markets observable unobservable investments measured identical assets inputs inputsa net asset valueb level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets investments fair value athe activity level assets significant years presented bper adoption asu certain investments measured fair value using net asset value per share equivalent practical expedient classified fair value hierarchy per asu prior year amounts reclassified conform current year presentation fair value amounts presented table intended permit reconciliation fair value hierarchy total retirement plan assets company 's benefit plans unfunded except us commingled funds level million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans repurchase common stock balance january aggregate shares common stock issued approximately shares end cash dividends paid per share compared dividends per share per share october company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash access capital markets january billion repurchased program july company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed april accumulated comprehensive income components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss december net changes december net changes january net changes january amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense netemployee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended january january december millions except per share amounts basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation included dilutive effect convertible debt offset related reduction interest expense million aftertax year million years diluted net earnings per share calculation included shares related stock options exercise price options less average market value company 's stock rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million respectively approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year january dollars millions total commitments capital leases significant common stock stock option plans stock compensation agreements january company stockbased compensation plans shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end compensation cost charged income plans million million million respectively total income tax benefit recognized income statement sharebasedcompensation costs million million million respectively additional tax benefit million recognized due adoption new accounting standard reporting additional tax benefits sharebased compensation described note total unrecognized compensation cost million million million respectively weighted average period cost recognized years years years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan january january december changes years ending dates presented aggregate weighted intrinsic average exercise value shares thousands outstanding shares price dollars millions shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares january total intrinsic value options exercised million million million respectivelythe following table summarizes stock options outstanding exercisable january shares thousands outstanding exercisable average average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding january december average life years average life years respectively stock options exercisable january december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return operational sales adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans january presented outstanding outstanding restricted share performance shares thousands units share units shares december granted issued canceledforfeited shares december granted issued canceledforfeited shares january granted issued canceledforfeited shares january average fair value restricted share units granted respectivelyusing fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted calculated using weighted average fair market value three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million million respectively segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices united states international total worldwide total income tax identifiable assets dollars millions consumer pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company two wholesalers distributing products three segments represented approximately total consolidated revenues company one wholesaler distributing products three segments represented approximately respectively total consolidated revenues amounts allocated segments include interest income expense general corporate income expense general corporate includes cash cash equivalents marketable securities includes net litigation expense million restructuring related charge million medical devices segment pharmaceutical segment includes positive adjustment billion previous reserve estimates inprocess research development expense million gains divestitures controlled substance raw material active pharmaceutical ingredient api business certain anesthetic products europe medical devices segment includes restructuring related charge million intangible asset writedown million related acclarent synthes integration costs million million expense cost associated depuy asrtm hip program includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively includes net litigation expense million comprised million pharmaceutical segment million medical devices segment included gain litigation settlement agreement guidant million medical devices segment includes gain billion divestiture cordis business pharmaceutical segment includes gain million us divestiture nucynta positive adjustment billion previous reserve estimates including managed medicaid rebates consumer segment includes gain million divestiture splenda brand includes net litigation expense million comprised million million million medical devices pharmaceutical consumer segments respectively includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively medical devices segment includes net gain million divestiture orthoclinical diagnostics business synthes integration costs million million expense cost associated depuy asrtm hip program pharmaceutical segment includes additional year branded prescription drug fee million positive adjustment billion previous reserve estimates longlived assets include property plant equipment net respectively intangible assets goodwill net respectively selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical medical devices total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter recast reflect adoption asu see note consolidated financial statements details first quarter includes restructuring charge million aftertax million beforetax net litigation expense million aftertax million beforetax second quarter includes restructuring charge million aftertax million beforetax net litigation expense million aftertax million beforetax third quarter includes restructuring charge million aftertax million beforetax net litigation expense million aftertax million beforetax fourth quarter includes restructuring charge million aftertax million beforetax net litigation expense million aftertax million beforetax first quarter includes net litigation gain million aftertax million beforetax million aftertax million beforetax costs associated depuy asrtm hip program second quarter includes net litigation expense million aftertax million beforetax third quarter includes net litigation expense million aftertax million beforetax fourth quarter includes restructuring charge million aftertax million beforetax million aftertax million beforetax impairment inprocess research development synthes integration costs million aftertax million beforetax additionally fourth quarter includes gain cordis divestiture business combinations divestitures certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included vogue international llc privatelyheld company focused marketing development distribution saloninfluenced nature inspired hair care personal products neuwave medical inc privatelyheld medical device company manufactures markets minimally invasive soft tissue microwave ablation systems neostrata company inc global leader dermocosmetics global rights commercialization rhinocort allergy spray outside united states excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill net purchase price vogue international llc billion primarily recorded amortizable intangible assets billion goodwill billion weighted average life billion total amortizable intangibles approximately years trademark asset values determined definite lives ranging years majority years goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes assets acquired recorded consumer segment fiscal third quarter company announced definitive agreement acquire abbott medical optics amo whollyowned subsidiary abbott laboratories billion cash acquisition include ophthalmic products related cataract surgery laser refractive surgery consumer eye health transaction closed february purchase price allocation progress expected result allocation significant value amortizable intangible assets residual recorded goodwill january subsequent year end company announced definitive transaction agreement company launch allcash tender offer switzerland acquire outstanding shares actelion ltd per share payable us dollars approximately billion part transaction immediately prior completion acquisition actelion spin drug discovery operations earlystage clinical development assets newly created swiss biopharmaceutical company rd newco shares rd newco listed six swiss exchange six distributed actelion 's shareholders stock dividend upon closing tender company initially hold shares rd newco rights additional rd newco equity convertible note actelion established leading franchise differentiated innovative products pulmonary arterial hypertension pah highly complementary existing portfolio company addition actelions specialty inmarket medicines latestage products consistent company 's efforts grow attractive complementary therapeutic areas serve patients serious illnesses significant unmet medical need closing subject demerger antitrust clearance customary closing conditions february subsequent year end company received binding offer integra lifesciences holdings corporation purchase codman neurosurgery business approximately billion subsequent year end company announced engaging process evaluate potential strategic options johnson johnson diabetes care companies specifically lifescan inc animas corporation calibra medical inc strategic options may include formation operating partnerships joint ventures strategic alliances sale businesses alternatives either separately together options evaluated determine best opportunity drive future growth maximize shareholder value assurance process result transaction strategic alternative kind therefore assets held sale january related announcement certain businesses acquired million cash million liabilities assumed assumed liabilities primarily represent fair value contingent consideration million acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included xo limited privatelyheld biopharmaceutical company developing antithrombin antibody novira therapeutics inc privately held clinicalstage biopharmaceutical company developing innovative therapies curative treatment chronic hepatitis b virus infection excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd primarily associated acquisitions xo limited novira therapeutics inc value iprd calculated using cash flow projections discounted inherent risk projects iprd related acquisition xo limited million associated recombinant human antibody developed mimic activity human antibody appears produce anticoagulated state without predisposition bleeding probability success factor used reflect inherent clinical regulatory risk discount rateapplied iprd related acquisition novira therapeutics inc million associated lead candidate nvr investigational small molecule directacting antiviral oral administration patients hbv inhibits hbv core capsid protein probability success factor used reflect inherent clinical regulatory risk discount rate applied certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions included covagen ag privatelyheld biopharmaceutical company specializing development multispecific protein therapeutics fynomab technology platform alios biopharma inc privatelyheld clinical stage biopharmaceutical company focused developing therapies viral diseases orsltm electrolyte ready todrink brand jagdale industries ltd excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions covagen ag alios biopharma inc value iprd calculated using cash flow projections discounted inherent risk projects iprd related acquisition alios biopharma inc million associated alios lead compound al orally administered antiviral therapy treatment infants respiratory syncytial virus rsv probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition covagen ag million associated covagens lead compound cova currently phase b study psoriasis holding potential treatment broad range inflammatory diseases including rheumatoid arthritis probability success factor used reflect inherent clinical regulatory risk discount rate applied company recorded charge impairment iprd related acquisition covagen ag company completed acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company entered two accelerated share repurchase asr agreements company settled remaining liabilities asr agreements company believes transactions asr agreement series related internal transactions consummated tax efficient manner accordance applicable law possible internal revenue service could assert one contrary positions challenge transactions tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest supplemental pro forma information accordance us gaap standards related business combinations goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position company divestitures included controlled substance raw material active pharmaceutical ingredient api business certain anesthetic products europe certain nonstrategic consumer brands pretax gains divestitures approximately billion company divestitures included cordis business cardinal health splenda brand heartland food products group us license rights nucynta tapentadol nucyntaer tapentadol extended release tablets nucynta tapentadol oral solution pretax gains divestitures approximately billion company divestitures included orthoclinical diagnostics business carlyle group ky brand reckitt benckiser group plc us certain markets benecol brand raisio plc pretax gains divestitures approximately billion company completed divestiture ortho clinical diagnostics business carlyle group approximately billion company recorded pretax gain approximately billion orthoclinical diagnostics ' results included company 's medical devices segment legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory mattersdiscussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions ability make estimates judgments affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period product liability johnson johnson certain subsidiaries involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages company believes substantial defenses feasible predict ultimate outcome litigation company established accruals product liability claims lawsuits compliance asc based currently available information cases may limited company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated certain matters company accrued additional amounts estimated costs associated settlements damages losses extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal xarelto johnson 's baby powder january us approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal respect xarelto respect johnson 's baby powder august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system used hip replacement surgery claims personal injury made depuy johnson johnson number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed cases filed federal courts united states organized multi district litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia ireland germany italy november depuy reached agreement courtappointed committee lawyers representing asr hip system plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august settlement covered approximately patients february depuy reached additional agreement effectively extends existing settlement program asr hip patients revision surgeries august prior february second agreement estimated cover approximately additional patients estimated cost agreements covered existing accruals settlement program expected bring close significant asr hip litigation activity united states however many lawsuits united states remain settlement program address litigation outside united states australia settlement reached representatives class action lawsuit pending federal court new south wales resolves claims majority asr hip patients country company continues receive information respect potential costs associated recall worldwide basis company established accruals costs associated depuy asr hip program related product liability litigation changes accruals may required future additional information becomes available claims personal injury also made depuy johnson johnson relating pinnacle acetabular cup system used hip replacement surgery number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed countries outside united states primarily unitedkingdom company established accrual defense costs connection product liability litigation associated pinnacle acetabular cup system changes accrual may required future additional information becomes available claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court southern district west virginia addition class actions individual personal injury cases claims commenced various countries outside united states including claims cases united kingdom netherlands belgium italy venezuela class actions israel australia canada seeking damages alleged injury resulting ethicon 's pelvic mesh devices company established accrual respect product liability litigation associated ethicon 's pelvic mesh products changes accrual may required future additional information becomes available claims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism related compounds lawsuits primarily filed state courts pennsylvania california missouri actions pending various courts united states canada number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases company established accrual respect product liability litigation associated risperdal changes accrual may required future additional information becomes available claims personal injury made janssen pharmaceuticals inc johnson johnson arising use xarelto oral anticoagulant number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court eastern district louisiana addition cases filed state courts across united states many cases consolidated state mass tort litigation philadelphia pennsylvania coordinated proceedings delaware california missouri class action lawsuits also filed canada company established accrual defense costs connection product liability litigation associated xarelto changes accrual may required future additional information becomes available claims personal injury made johnson johnson consumer inc johnson johnson arising use johnson 's baby powder number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases lawsuits primarily filed state courts missouri new jersey california addition federal multidistrict litigation proceeding created litigation district court new jersey company established accrual defense costs connection product liability litigation associated johnson 's baby powder changes accrual may required future additional information becomes available intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result noncash impairment charge associated intangible asset significant matters described medical devices june rembrandt vision technologies lp rembrandt filed patent infringement lawsuit johnson johnson vision care inc jjvci united states district court eastern district texas alleging jjvci 's manufacture sale acuvue advance acuvue oasys hydrogel contact lenses infringe us patent ' patent rembrandt seeking monetary relief case transferred united states district court middle district florida may jury returned verdict holding neither accused lenses infringes ' patent rembrandt appealed august united states court appeals federal circuit affirmed district court 's judgment rembrandt asked district court grant new trial based alleged new evidence july district court denied rembrandts motion rembrandt appealed court appeals overturned ruling april remanded case district court new trial jjvci 's motion reconsider petition review united states supreme court denied new trial scheduled august december state israel filed lawsuit district court tel aviv jaffa omrix biopharmaceuticals inc various affiliates omrix lawsuit state claimed employee governmentowned hospital inventor several patents related fibrin glue technology employee developed government employee state claimed right transfer intellectual property omrix belongs state state sought damages plus royalties quixil evicel products alternatively transfer patents state case settled december lifescan filed patent infringement lawsuit unistrip technologies llc unistrip united states district court district north carolina may alleging making marketing unistrips strips use lifescans blood glucose monitors infringe us patent nos ' patent ' patent august united states patent trademark office uspto determined ' patent invalid january invalidity decision upheld appeal lifescan filed motion rehearing denied july unistrip brought lawsuit lifescan united states district court eastern district pennsylvania alleging antitrust violations relating marketing practices lifescan strips march medinol ltd medinol filed patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york alleging cordis 's sales cypher cypher select stents made united states since willfully infringed four medinol 's patents directed geometry articulated stents medinol seeking damages attorneys ' fees trial january district court dismissed case finding medinol unreasonably delayed bringing claims medinol appeal decision september district court denied motion medinol vacate judgment grant new trial medinol 's appeal decision dismissed medinol filed petition review united states supreme court cordis divested company retained liability may result case november medidea llc medidea filed patent infringement lawsuit depuy orthopaedics inc united states district court northern district illinois alleging infringement attune knee system two patents relating posterior stabilized knee systems specifically medidea alleges sofcamtm contact feature attune posterior stabilized knee products infringes patentsinsuit medidea seeking monetary damages injunctive relief december ethicon endosurgery inc ethicon endosurgery llc known ethicon llc sued covidien inc us district court district massachusetts seeking declaration covidiens us patent nos either invalid infringed ethicons enseal x large jaw tissue sealer product enseal x enseal x product scheduled launch united states europe first quarter pharmaceutical april morphosys ag german biotech company filed patent infringement lawsuit janssen biotech inc jbi genmab us inc genmab collectively genmab united states district court district delaware alleging jbis manufacture sale darzalex daratumumab willfully infringes morphosys ' us patent morphosys seeking money damages jbi licenses patents commercial rights darzalex genmab june jbi filed motion dismiss lawsuit november morphosys sought leave add another patent case us patent february court granted request trial case currently scheduled commence august august sandoz ltd hexal ag collectively sandoz filed lawsuit english high court gd searle llc pfizer company janssen sciences ireland uc jsi alleging searles supplementary protection certificate spcgb spc exclusively licensed jsi invalid revoked janssencilag limited sells prezista darunavir uk pursuant license october searle jsi counterclaimed sandoz threatened infringement spc based statements plans launch generic darunavir uk trial case hasbeen scheduled begin late aprilearly may remicade related cases us proceedings september janssen biotech inc jbi nyu langone medical center nyu received office action united states patent trademark office uspto rejecting claims us patent relating remicade infliximab ' patent reexamination proceeding instituted third party ' patent coowned jbi nyu nyu granted jbi exclusive license nyus rights patent ' patent expires september following several office actions patent examiner including two rejections responses jbi uspto issued action maintaining rejection ' patent jbi filed notice appeal uspto 's patent trial appeal board november patent trial appeal board issued decision upholding examiner 's rejection jbi filed appeal us court appeals federal circuit august celltrion healthcare co ltd celltrion inc together celltrion filed application us food drug administration fda approval make sell infliximab biosimilar march jbi filed lawsuit united states district court district massachusetts celltrion hospira healthcare corporation hospira exclusive us marketing rights celltrion 's infliximab biosimilar seeking among things declaratory judgment biosimilar product infringes potentially infringes several jbi patents including ' patent us patent ' patent august district court granted celltrion 's hospira 's motions summary judgment invalidity ' patent jbi appealed decisions us court appeals federal circuit case appeal reexamination ' patent designated companion cases heard panel judges federal circuit june jbi filed two additional patent infringement lawsuits asserting ' patent one celltrion united states district court district massachusetts hyclone laboratories inc manufacturer cell culture media celltrion uses make biosimilar product united states district court district utah although ' patent already asserted existing lawsuit celltrion additional lawsuit expands claims include use cell culture media made united states manufacture celltrion 's biosimilar additional lawsuit celltrion consolidated existing lawsuit discussed hospira moved dismiss counts lawsuit related ' patent celltrion moved dismiss counts lawsuit related ' patent without prejudice failure join coowners patent plaintiffs trial postponed pending resolution motions fda approved celltrions infliximab biosimilar sale united states april day period notice launch biosimilar product biologics price competition innovation act passed hospira 's parent company pfizer inc began shipment celltrion 's infliximab biosimilar wholesalers united states late november introduction us market biosimilar result reduction us sales remicade canadian proceedings march hospira filed impeachment proceeding kennedy institute rheumatology kennedy challenging validity canadian patent related remicade feldman patent exclusively licensed jbi october kennedy along jbi janssen inc janssen cilag gmbh international affiliates jbi filed counterclaim infringement celltrion hospira counterclaim alleges products described celltrions hospiras marketing applications health canada subsequent entry biologics seb remicade would infringe feldman patents owned kennedy trial patent action concluded october closing arguments took place january parties awaiting decision january health canada approved celltrions seb remicade allowing celltrion market infliximab biosimilar canada regardless pending patent action june health canada approved hospiras seb remicade july janssen filed lawsuit compel canadian minister health withdraw notice compliance hospiras seb hospira serve notice allegation janssen address patent listed janssen patent register march parties entered settlement agreement whereby health canada agreed consent judgment setting aside hospiras notice compliance subject health canada 's appeal filed june nevertheless hospira began marketing infliximab biosimilar distributor celltrion 's notice compliance october appeals court reversed consent judgment janssen filed application leave appeal supreme court canada hospira continues market sell celltrion 's infliximab biosimilar canadain canada remicade patent discussed found invalid following appeals could relied upon prevent introduction infliximab biosimilars prior august expiry date patent litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed abbreviated new drug applications andas fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability applicable patents event subsidiaries successful actions statutory month stays andas expire united states district court rulings obtained thirdparty companies involved ability upon approval fda introduce generic versions products issue market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset addition time time subsidiaries may settle actions settlements involve introduction generic versions products issue market prior expiration relevant patents inter partes review ipr process united states patent trademark office uspto created america invents act also used generic companies conjunction andas lawsuits challenge patents held companys subsidiaries concerta december janssen inc alza corporation filed notice application actavis pharma company actavis response actavis notice allegation seeking approval market generic version concerta expiration canadian patent ' patent december canadian federal court allowed application issued order preventing actavis obtaining marketing approval notice compliance generic version concerta expiration ' patent actavis commence appeal prior deadline thus prevented obtaining notice compliance generic version concerta expiration ' patent october alza corporation janssen pharmaceuticals inc filed patent infringement lawsuit us district court district delaware amneal pharmaceuticals new york llc amneal pharmaceuticals llc response amneals anda seeking approval market generic version concerta expiration united states patent nos november amneal filed motion judgment pleadings arguing certain claims patents invalid others infringed janssen opposed motion zytiga june july janssen biotech inc jbi received notices paragraph iv certification several companies advising respective andas seeking approval generic version zytiga expiration one patents relating zytiga july jbi janssen oncology inc janssen oncology janssen research development llc collectively janssen btg international ltd btg filed patent infringement lawsuit united states district court district new jersey several generic anda applicants certain affiliates andor suppliers response respective andas seeking approval market generic version zytiga expiration united states patent nos ' patent andor ' patent generic companies include actavis laboratories fl inc actavis amneal pharmaceuticals llc amneal pharmaceuticals new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron dr reddys laboratories ltd dr reddys laboratories inc collectively dr reddy 's mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par sun pharmaceutical industries ltd sun pharmaceuticals industries inc collectively sun teva pharmaceuticals usa inc teva wockhardt bio ag wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma court entered stay lawsuit par citron agreed bound decision defendants action ' patent expired december thus infringement actions concern ' patent february court set trial date october august janssen btg filed additional jurisdictional protective lawsuit mylan defendants united states district court northern district west virginia stayedin august janssen received notice paragraph iv certification hetero usa inc us regulatory agent hetero labs limited unitv division hetero labs limited collectively hetero advising heteros anda seeking approval generic version zytiga expiration ' patent september janssen btg filed amended complaint new jersey lawsuit add alleged infringement ' patent hetero march janssen filed motion new jersey lawsuit correct inventorship ' patent add inventor granted leave amend complaint accordingly january court granted janssen 's motion janssen filed second amended complaint adding btg coowner ' patent coplaintiff regarding ' patent infringement claims march janssen received notice amerigen pharmaceuticals limited amerigen advising amerigens anda seeking approval generic version zytiga expiration ' patent response janssen btg filed separate patent infringement lawsuit united states district court district new jersey amerigen may may janssen received notice paragraph iv certification glenmark pharmaceuticals inc behalf glenmark pharmaceuticals sa wholly owned subsidiary glenmark pharmaceuticals ltd collectively glenmark advising glenmarks anda seeking approval generic version zytiga expiration ' patent response june janssen btg filed patent infringement lawsuit united states district court district new jersey glenmark parties stipulated dismissal glenmark pharmaceuticals ltd filing abovereferenced lawsuits triggered stay october time fda grant final approval generics ' andas unless earlier district court decision finding patentsinsuit invalid infringed lawsuits janssen seeking order enjoining defendants marketing generic versions zytiga expiration relevant patents december amerigen filed petition inter partes review uspto seeking invalidate ' patent may uspto granted inter partes review decision validity patent expected may june argentum pharmaceuticals llc mylan pharmaceuticals inc filed petitions inter partes review uspto seeking invalidate ' patent moved join inter partes review filed amerigen uspto instituted argentum 's petition granted argentum 's motion joinder january granted mylan 's petition inter partes review denied mylan 's motion joinder august wockhardt bio ag filed petition inter partes review uspto seeking invalidate ' patent uspto granted january february actavis amneal dr reddy 's sun teva westward hikma filed joint petition inter partes review uspto seeking invalidate ' patent moved join inter partes review filed mylan complera august september janssen pharmaceutica nv janssen sciences ireland uc collectively janssen gilead sciences inc gilead sciences ireland uc collectively gilead filed patent infringement lawsuits united states district courts district delaware district west virginia respectively mylan inc mylan pharmaceuticals inc collectively mylan response mylans anda seeking approval market generic version complera expiration united states patent nos ' patent ' patent ' patent west virginia action september mylan filed answer counterclaims asserting invalidity noninfringement ' patent ' patent ' patent well united states patent patent march district west virginia court stayed lawsuit scheduled conditional trial date february accordance schedule firstfiled delaware lawsuit described delaware action january march janssen gilead amended complaint add claims patent infringement respect patent united states patent nos ' patent ' patent ' patent ' patent mylan filed motion dismiss suit lack personal jurisdiction motion dismiss strike sever infringement claims regarding patents september delaware district court denied mylans motions trial delaware action scheduled forfebruary lawsuits janssen seeking order enjoining defendants marketing generic versions complera expiration relevant patents xarelto number generic companies filed andas seeking approval market generic versions xarelto october janssen pharmaceuticals inc jpi bayer pharma ag bayer intellectual property gmbh collectively bayer filed patent infringement lawsuits united states district court district delaware aurobindo pharma limited aurobindo pharma usa inc breckenridge pharmaceutical inc micro labs usa inc micro labs ltd collectively micro mylan pharmaceuticals inc mylan inc mylan prinston pharmaceutical inc sigmapharm laboratories llc torrent pharmaceuticals limited torrent pharma inc response parties respective andas seeking approval market generic versions xarelto expiration bayers united states patent nos patent patent patent relating xarelto jpi exclusive licensee asserted patents november mylan moved dismiss action december jpi bayer mylan stipulated agreed dismiss claims mylan suspend briefing argument mylan 's motion dismiss pending appeals relating personal jurisdiction mylan pharmaceuticals inc district delaware february similar patent infringement action jpi bayer invagen pharmaceuticals inc invagen response invagens notice paragraph iv certification advising anda seeking fda approval generic xarelto product expiration relevant patents consolidated original case district court set trial date march april jpi bayer filed separate patent infringement action district delaware micro response notice paragraph iv certification advising anda seeking fda approval generic xarelto product expiration patents may action consolidated original action july jpi bayer filed separate patent infringement action district delaware breckenridge pharmaceutical inc response notice paragraph iv certification advising anda seeking fda approval generic xarelto product expiration patents action consolidated original action lawsuits jpi seeking order enjoining defendants marketing generic versions xarelto expiration relevant patents october mylan filed petitions inter partes review uspto seeking invalidate patents government proceedings like companies pharmaceutical medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate result interaction government agencies ongoing significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl united states district court district massachusetts plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp june trial merits mdl court dismissed theclaims two plaintiff classes jj awp defendants march court dismissed claims third class jj awp defendants without prejudice awp cases brought various attorneys general proceeded trial manufacturers several state cases certain johnson johnson subsidiaries settled including case wisconsin settled february cases still pending illinois new jersey utah cases illinois new jersey yet proceeded trial utah claims brought attorney general dismissed court state may appeal dismissal conclusion similar pending matters defendants awp case jj awp defendants brought commonwealth pennsylvania following trial pennsylvania commonwealth court found favor commonwealth regard certain claims pennsylvania unfair trade practices consumer protection law favor jj awp defendants commonwealths remaining claims following appeal pennsylvania supreme court vacated judgment commonwealth court entered subsequent judgment favor jj awp defendants claims subsequent judgment upheld pennsylvania supreme court successive appeal mcneil consumer healthcare starting june mcneil consumer healthcare division mcneilppc inc johnson johnson consumer inc mcneil consumer healthcare division mcneil consumer healthcare certain affiliates including johnson johnson companies received grand jury subpoenas united states attorney 's office eastern district pennsylvania requesting documents broadly relating recalls various products mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacturing facilities well certain documents relating recalls small number products subsidiaries addition february government served mcneilppc inc johnson johnson consumer inc jjci civil investigative demand seeking records relevant investigation determine violation federal false claims act march mcneilppc inc jjci entered guilty plea united states district court eastern district pennsylvania misdemeanor violation us food drug cosmetic act mcneilppc inc jjci agreed pay million fine million forfeiture resolve matter companies also received civil investigative demands multiple state attorneys general offices broadly relating mcneil recall issues companies continue cooperate inquiries coordinated multistate coalition resolution reached multistate coalition possible individual state attorneys general offices may file civil monetary claims companies january oregon attorney general filed civil complaint johnson johnson mcneilppc inc jjci mcneil healthcare llc state court alleging civil violations oregon unlawful trade practices act relating earlier recall mcneil otc product november state court granted motion companies dismiss oregon 's complaint entirety prejudice november state court appeals reversed trial court reinstated oregon 's consumer protection claims february oregon supreme court denied companies ' petition review case sent back trial court opioids litigation described johnson johnson jj janssen pharmaceuticals inc jpi along pharmaceutical companies named four lawsuits alleging claims related marketing opioids including duragesic nucynta nucynta er subpoenaed two states information related opioid marketing practices may santa clara orange counties california filed complaint state court orange county california numerous pharmaceutical manufacturers including jj jpi alleging claims related opioid marketing practices including false advertising unfair competition public nuisance counties seek injunctive monetary relief february defendants filed motions challenging sufficiency complaint august court stayed case fda concludes ongoing inquiry safety effectiveness longterm opioid treatment following motion counties lift stay october court kept stay place part requested parties confer adjourned matter later date june city chicago filed complaint cook county circuit court group pharmaceutical manufacturers including jj jpi alleging number claims related opioid marketing practices including consumer fraud violations false claims seeking injunctive monetary relief case later removed united states district court northern district illinois december jj jpi filed motion dismiss city ofchicago 's first amended complaint granted leave file amended complaint city filed second amended complaint november jj jpi filed motion dismiss second amended complaint september court dismissed eight citys ten causes action granted city one final opportunity replead dismissed claims city filed third amended complaint october december jj jpi filed answer two causes action motion dismiss remaining causes action september tennessee attorney general division consumer affairs issued request information jpi pharmaceutical companies related opioids marketing practices august new hampshire attorney general consumer protection antitrust bureau issued subpoena jpi pharmaceutical companies related opioids marketing practices october state filed motion state new hampshire superior court enforce subpoena jpi pharmaceutical companies subsequently filed joint motion injunctive relief protective order preclude state engaging private contingent fee counsel participate states investigation subsequent enforcement action march court granted protective order grounds state obtained requisite executive legislative approvals retain private counsel rejected contention contingency fee agreement otherwise unlawful parties appealed march ruling new hampshire supreme court august court denied pharmaceutical companies joint motion enforce protective order ground underlying deficiency legislative approval cured september state stipulated stay enforcement subpoenas pending new hampshire supreme courts consideration companies appeal march ruling december state mississippi filed complaint chancery court first judicial district hinds county substantially group pharmaceutical manufacturers suits brought california counties city chicago including jj jpi alleging number claims related opioid marketing practices seeking penalties injunctive monetary relief march defendants filed motion transfer venue motions dismiss complaint august county suffolk new york filed complaint several pharmaceutical manufacturers new york supreme court including jj jpi alleging claims related opioid marketing including claims based deceptive acts practices false advertising fraud unjust enrichment complaint seeks penalties injunctive monetary relief february county erie county broome new york filed complaint new york supreme court several pharmaceutical manufacturers including jpi complaints allege claims related opioid marketing practices including statutory claims deceptive acts practices false advertising violation new yorks social services law common law causes action public nuisance fraud unjust enrichment county seeking compensatory punitive damages costs september synthes inc synthes received civil investigative demand issued pursuant false claims act united states attorney 's office eastern district pennsylvania demand sought information regarding allegations fellowships offered hospitals exchange agreements purchase products synthes produced documents information response demand cooperating inquiry may acclarent inc acclarent received subpoena united states attorney 's office district massachusetts requesting documents broadly relating sales marketing alleged offlabel promotion acclarent relieva stratus microflow spacer product relieva stratus spacer march acclarent executed civil settlement united states justice department agencies resolve investigation johnson johnson party settlement admission liability separate matter july former presidentceo vice president sales acclarent former acclarent officers convicted misdemeanor violations connection sale marketing relieva stratus spacer charges acclarent ethicon inc johnson johnson matter august depuy orthopaedics inc depuy inc depuy synthes inc johnson johnson services inc received informal request united states attorney 's office district massachusetts civil division united states department justice united states production materials relating depuy asr xl hip device july united states notified united states district court district massachusetts haddeclined intervene qui tam case filed pursuant false claims act companies february district court granted companies motion dismiss prejudice unsealed qui tam complaint denied qui tam relators request leave file amended complaint qui tam relators appealed case united states court appeals first circuit first circuit 's decision case pending since october group state attorneys general issued civil investigative demands relating development sales marketing several depuy orthopaedics inc 's hip products states seeking monetary injunctive relief july oregon department justice investigating matters independently states announced settlement asr xl hip device investigation total payment million state oregon october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson 's subsidiary ethicon inc ethicon johnson johnson ethicon since entered series tolling agreements states district columbia participating multistate investigation responded civil investigative demands served certain participating states states seeking monetary injunctive relief may california washington filed civil complaints johnson johnson ethicon alleging violations consumer protection statutes august kentucky filed similar complaint companies johnson johnson ethicon entered new tolling agreement remaining states district columbia december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts system period present united states attorney 's office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp january ocd divested june following divestiture ocd johnson johnson retains ocds portion liability may result investigation activity occurred prior sale therakos march march united states attorneys office requested johnson johnson produce certain documents johnson johnson cooperating requests june mississippi attorney general filed complaint chancery court first judicial district hinds county mississippi johnson johnson johnson johnson consumer companies inc johnson johnson consumer inc jjci complaint alleges defendants failed disclose alleged health risks associated female consumers ' use talc contained johnson 's baby powder johnson 's shower shower product longer sold jjci seeks injunctive monetary relief matter currently scheduled trial september march janssen pharmaceuticals inc jpi received civil investigative demand united states attorneys office southern district new york related jpis contractual relationships pharmacy benefit managers period january present regard certain jpi 's pharmaceutical products demand issued connection investigation false claims act january janssen pharmaceuticals inc jpi received civil investigative demand cid united states department justice doj relating allegations concerning sales marketing practices olysiotm jpi cooperating doj appropriately responding cid february johnson johnson received subpoena united states attorney 's office district massachusetts seeking production records pertaining payments c charitable organization provides financial assistance medicare patients multiple pharmaceutical companies publicly reported receipt similar subpoenas ongoing inquiries recent years johnson johnson received numerous requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation june following public announcement orthoclinical diagnostics inc ocd received grand jury subpoena united states department justice antitrust division connection investigation since closed multiple class action complaints filed ocd direct purchasers seeking damages alleged pricefixing cases consolidated pretrial purposes united states district court eastern district pennsylvania blood reagent antitrust litigation august district court granted motion filed plaintiffs class certification april united states court appeals third circuit reversed class certification ruling remanded case district court proceedings october district court granted motion plaintiffs class certification july ocd filed motion summary judgment ocd divested johnson johnson retained liability may result cases september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc received notice civil claim filed nick field supreme court british columbia canada bc civil claim bc civil claim putative class action brought behalf persons reside british columbia purchased period september december one various mcneil infants ' children 's overthecounter medicines manufactured fort washington pennsylvania facility bc civil claim alleges defendants violated bc business practices consumer protection act canadian statutes common laws selling medicines allegedly safe andor effective comply canadian good manufacturing practices class certification hearing scheduled october adjourned currently date set hearing may two purported class actions filed federal court one united states district court central district california one united states district court southern district illinois johnson johnson jj johnson johnson consumer companies inc johnson johnson consumer inc jjci alleging violations state consumer fraud statutes based nondisclosure alleged health risks associated talc contained johnson 's baby powder johnson 's shower shower product longer sold jjci cases seek injunctive relief monetary damages neither includes claim personal injuries october cases transferred united states district court district court new jersey part newly created federal multidistrict litigation december jj jjci filed motion dismiss one cases august united states customs border protection us cbp issued penalty notice janssen ortho llc janssen ortho assessing penalties alleged improper classification darunavir ethanolate active pharmaceutical ingredient prezista connection importation united states october janssen ortho submitted petition relief response penalty notice may us cbp issued amended penalty notice assessing substantial penalties janssen ortho filed petition relief july march april putative class action complaints filed contact lens patients number courts around united states johnson johnson vision care inc jjvci contact lens manufacturers distributors retailers alleging vertical horizontal conspiracies fix retail prices contact lenses complaints allege manufacturers reached agreements certain distributors retailers concerning prices contact lenses could sold consumers plaintiffs seeking damages injunctive relief class action cases transferred united states district court middle district florida june plaintiffs filed consolidated class action complaint november december jjvci defendants filed motions dismiss june court denied motions dismiss discovery ongoing april johnson johnson vision care inc jjvci filed complaint united states district court district utah state utah seeking declaratory judgment law passed state ban unilateral pricing policies solely contact lens market violates commerce clause united states constitution court denied jjvci 's motion preliminary injunction jjvci appealed argument appeal held august december appellate court denied jjvci 's appeal april adimmune corporation ltd adimmune commenced arbitration international court arbitration international chamber commerce crucell switzerland ag janssen vaccines ag crucell holland bv janssen vaccines prevention bv collectively crucell adimmune claims crucell breached certain agreements relating supply flu antigen crucell ceased purchasing flu antigen adimmune december adimmune filed statement claim seeking monetary damages arbitration hearing took place november parties awaiting ruling august two thirdparty payors filed purported class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc orthomcneil janssen pharmaceuticals inc johnson johnson well certain bayer entities alleging defendants improperly marketed promoted xarelto safer effective less expensive alternative medications failing fully disclose risks complaint seeks damages unspecified amount johnson johnson subsidiaries also parties number proceedings brought comprehensiveenvironmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation restructuring company announced restructuring actions medical devices segment better serve needs patients customers todays evolving healthcare marketplace company undertaking actions strengthen gotomarket model accelerate pace innovation prioritize key platforms geographies streamline operations maintaining high quality standards company estimates connection plans record pretax restructuring related charges approximately billion billion company recorded pretax charge million million included cost products sold million included income expense see table additional details total project costs billion recorded since restructuring announced additionally part plan company expects restructuring actions result position eliminations approximately percent medical devices segments global workforce next two years subject consultation procedures countries required approximately positions eliminated since restructuring announced company estimates approximately onehalf cumulative pretax costs result cash outlays including approximately million employee severance approximately one half cumulative pretax costs noncash relating primarily facility rationalization inventory writeoffs intangible asset writeoffs following table summarizes severance charges associated spending initiative fiscal year ended dollars millions severance asset writeoffs total restructuring charge activity reserve balance january current year activity charges cash payments settled non cash reserve balance january cash outlays severance expected substantially paid next months accordance company 's plans local laws includes project expense salaries employees supporting initiative consulting expenses report independent registered public accounting firm shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings comprehensive income equity cash flows present fairly material respects financial position johnson johnson subsidiaries january january results operations cash flows three years period ended january conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting january based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions discussed note consolidated financial statements company changed manner accounts presents certain elements share based payments companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded january companys internal control financial reporting effective effectiveness companys internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky dominic j caruso alex gorsky dominic j caruso chairman board directors executive vice president chief financial officer chief executive officer shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer dominic j caruso executive vice president chief financial officer reviewed participated evaluation based evaluation messrs gorsky caruso concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended january changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption item election directors board committees material captions item election directors stock ownership section compliance section beneficial ownership reporting compliance proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act code business conduct available companys website wwwjnjcomcode ofbusinessconduct copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovboardconductcfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendmentto code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption item stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report equity compensation plan information following table provides certain information january concerning shares companys common stock may issued existing equity compensation plans number securities weighted issued upon average exercise exercise price number securities outstanding outstanding remaining available options options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions item election directors director independence related party transactions proxy statement item principal accountant fees services information called item incorporated herein reference material caption item ratification appointment independent registered public accounting firm proxy statement part iv item